Thermo Fisher Scientific has entered a definitive agreement to sell its microbiology business to private equity firm Astorg. The transaction is expected to close in the second half of 2026.
- Sale price of $1.075 billion including a $50 million seller note
- Microbiology unit 2025 revenue stood at $645 million
- Expected EPS dilution of $0.15 in the first full year
- Closing expected in H2 2026
- Further guidance to be provided during Q2 earnings call
Sign up free to read the full analysis
Create a free account to unlock full AI-curated market articles, personalized alerts, and more.